Literature DB >> 6940313

Relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4'-epi-doxorubicin in guinea pig heart muscle.

F Villani, L Favalli, F Piccinini.   

Abstract

Doxorubicin and 4'-epi-doxorubicin, two anthracycline derivatives with different cardiotoxic effects in experimental models, were found to decrease myocardial contractility in isolated guinea pig atria by significantly modifying calcium turnover. This effect seems to be mainly localized on the fast exchanging membrane-bound calcium, while these drugs do not significantly influence the intracellular stores of calcium. 4'-epi-doxorubicin, which induces a less negative inotropic effect than doxorubicin, produces a smaller inhibition of calcium turnover. This supports the hypothesis that the inhibition of calcium turnover and particularly of the fast exchanging calcium compartment is a general mechanism involved in the early anthracycline-induced cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6940313     DOI: 10.1177/030089168006600603

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

1.  Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.

Authors:  D A Vorobiof; M Iturralde; G Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Covalent protein binding of reactive adriamycin metabolites in rat liver and rat heart microsomes.

Authors:  M E Scheulen; H Kappus; A Nienhaus; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  4'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors.

Authors:  J Schütte; N Niederle; B Grunenberg; W Krischke; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

5.  Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).

Authors:  E E Holdener; H H Hansen; H Høst; U Bruntsch; F Cavalli; J Renard; H M Pinedo; M Rozencweig
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  SEM observations on the effect of anthracycline drugs on cultured newborn rat cardiomyocytes.

Authors:  M Djaldetti; R Gilgal; A Shainberg; B Klein; I Zahavi
Journal:  Basic Res Cardiol       Date:  1988 Nov-Dec       Impact factor: 17.165

Review 7.  The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.

Authors:  A Goldin; J M Venditti; R Geran
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.